In recent years, the Orf virus (ORFV) has become a promising tool for protective recombinant vaccines and oncolytic therapy. Regardless of the high potential for use and the broad range of possible applications, enhancing the purity of the final product, and consequentially, decreasing the negative impacts attributed to impurities is essential. Accurate and comprehensive analytical data plays an important role in process development. However, analytical methods available for characterizing ORFV components at various phases of production, including upstream and downstream processes are rather limited.
For this purpose, we developed a high-performance liquid chromatography (HPLC) PATfix® analytical method, based on multiple-detector PATfix technology coupled with CIMac QA-0.1 (6 μm) analytical column, enabling us to assess sample composition at various stages of ORFV production and determination of ORFV particles.